Share This

PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
Ribobay Pharma boosts CRDMO offerings with Cytiva's first FlexFactory platform for oligonucleotides
FlexFactory platform for oligonucleotides, an integrated solution to boost efficiency and speed of pharmaceutical manufacturing to meet market demand SHANGHAI , May 10, 2024 /PRNewswire/ -- ...
2024-05-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
The biotech company continues to offer hope to systemic lupus erythematosus  ( SLE) patients globally by sharing the latest developments of its proprietary novel fusion protein drug Telitacicept ...
2024-05-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval
CHENGDU, China , May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, ...
2024-05-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer
SEOUL, South Korea , May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young -hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) ...
2024-05-10T    Health Care/Hospital   Medical/Pharmaceuticals 
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost
Adalimumab-aaty will be priced at an 85% discount to HUMIRA ® (adalimumab) Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients ...
2024-05-10T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology
First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias. ...
2024-05-09T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
FDA Clears the Individualized Nomogram for Rika Plasma Donation System
The latest innovation is anticipated to increase collection volume without increasing collection time ...
2024-05-09T    Health Care/Hospital   Medical/Pharmaceuticals 
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic ...
2024-05-09T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic ...
2024-05-09T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI , May 9, 2024 /PRNewswire/ -- Taiwan -based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with ...
2024-05-09T    Banking/Financial Service   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.